QurAlis picked up $88 million for two Phase I studies, hoping to ride regulatory waves driven by the recent FDA approval of Amylyx Pharmaceuticals’ ALS therapy. Four biopharmas — Eli Lilly, Amgen, Sanofi and Mitsubishi Tanabe’s VC arm — are bankrolling a Series B for the biotech from Harvard stem cell
This content was originally published here.
